Document what Purdue Pharma's internal records — available since the 2007 federal guilty plea and expanded through subsequent litigation — show the company knew about OxyContin's addiction risk and 12-hour dosing failure, and when they knew it, relative to their public statements.

Primary document analysis: Massachusetts AG 2019 complaint and exhibits (internal Purdue emails and sales data), 2007 federal plea agreement documents, Purdue bankruptcy filings, and peer-reviewed literature on opioid epidemic epidemiology including CDC mortality data.

What Is Documented

I want to establish at the outset that the Purdue Pharma case is unusual in one specific respect: we have the internal documents. The 2007 federal guilty plea by Purdue Frederick (Purdue's subsidiary) and its three top executives required disclosure of internal records.

Subsequent litigation by state attorneys general — particularly the Massachusetts AG's 2019 complaint, which was unusually detailed — included internal emails, sales reports, and executive communications. The documents are public. This is not a story about inference from circumstantial evidence. It is a story about what the internal records say.

The 12-Hour Dosing Claim

OxyContin was approved in 1995 on the basis that its controlled-release formulation maintained effective blood levels for 12 hours, meaning it could be dosed twice daily rather than every 4-6 hours like immediate-release opioids.

This 12-hour dosing claim was the commercial foundation of the product — it differentiated OxyContin from generic oxycodone and supported the argument that it had lower abuse potential because the slow release prevented the rapid peak plasma levels associated with euphoria.

Internal Purdue documents from the late 1990s, reviewed by journalists at the Los Angeles Times (2016) and subsequently by researchers, show that Purdue sales representatives were reporting patient complaints that OxyContin was wearing off before 12 hours — causing patients to experience pain and early withdrawal symptoms in the gap between doses.

This is a clinically significant finding. A patient who experiences withdrawal symptoms at 10-11 hours has become physically dependent and is experiencing a cycle that drives dose escalation.

Purdue's response to these field reports, documented in internal communications, was to instruct sales representatives to tell physicians to increase the dose — not to shorten the dosing interval. Increasing the dose resolved the end-of-dose failure problem in the short term. It also produced patients on higher doses, which generated more revenue and more physical dependence.

I want to be precise: I am not claiming Purdue executives decided in a meeting to cause an addiction epidemic. I am claiming that internal documents show they received reports of a clinical problem that indicated their 12-hour efficacy claim was not accurate for a significant proportion of patients, and their documented response was one that increased doses rather than corrected the claim.

The Addiction Risk Misrepresentation

Purdue's marketing materials and sales training from the 1990s and 2000s stated that the risk of addiction from OxyContin was "less than one percent."

This claim derived from a five-sentence letter published in the New England Journal of Medicine in 1980 by Jane Porter and Hershel Jick — a letter that reported on 11,882 hospital patients who received opioids and found rare addiction in those with "no history of addiction." This was not a study of OxyContin. It was not a study of long-term outpatient opioid use.

It was a letter about hospitalized patients receiving opioids for acute pain management.

The NEJM letter was cited in the peer-reviewed literature over 600 times, increasingly without qualification. Purdue's sales materials cited it to support the claim that OxyContin was not addictive.

The authors of the letter — in a letter to the editor published in NEJM in 2017, after Jick had long since retired — wrote that they were "mortified" by the misuse of their work and that their 1980 letter had "had a significant impact on the opioid crisis by helping to develop a narrative that it was safe to use opioids for chronic non-cancer pain."

The Sackler family, which owned Purdue, received approximately $10-12 billion in distributions from Purdue between 2008 and 2018, the period of peak OxyContin revenue. This figure comes from the Massachusetts AG complaint and Purdue's bankruptcy proceedings.

The Body Count Arithmetic

The CDC estimates that approximately 500,000 people died from opioid overdoses between 1999 and 2019. Prescription opioids are directly implicated in approximately 247,000 of those deaths. I am not attributing all prescription opioid deaths to Purdue specifically — other manufacturers and distributors contributed substantially and were named in litigation.

I am noting that Purdue's conduct occurred during the period when prescription opioid death rates were rising, that their internal documents show they were aware of addiction and dosing problems they did not publicly disclose, and that the Sackler family extracted $10-12 billion while this was happening.

Purdue filed for bankruptcy in 2019. The Sackler family's initial settlement proposal offered $3 billion. Under the terms eventually negotiated, the Sacklers paid approximately $6 billion and received broad civil liability releases. No member of the Sackler family has been criminally convicted.

Richard Sackler, former president of Purdue, received a patent in 2018 — while the litigation was active — for a new formulation of buprenorphine to treat opioid addiction. I am including this fact without additional commentary because I think it speaks for itself in a way that additional commentary would only diminish.